OTCMKTS:ARTH Arch Therapeutics (ARTH) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free ARTH Stock Alerts $1.18 +0.04 (+3.51%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$1.15▼$1.2050-Day Range$1.05▼$3.0052-Week Range$0.39▼$18.00Volume618 shsAverage Volume3,850 shsMarket Capitalization$5.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Arch Therapeutics alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Arch Therapeutics Stock (OTCMKTS:ARTH)Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.Read More ARTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARTH Stock News HeadlinesApril 20, 2024 | americanbankingnews.comArch Therapeutics (OTCMKTS:ARTH) Share Price Crosses Below 50 Day Moving Average of $2.06February 8, 2024 | msn.comArch Therapeutics Secures $750K Prepayment for StockApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.January 6, 2024 | morningstar.comArch Therapeutics Inc ARTHNovember 23, 2023 | msn.comAre Medical Stocks Lagging Arch Therapeutics (ARTH) This Year?November 9, 2023 | finanznachrichten.deArch Therapeutics, Inc.: Arch Therapeutics Provides Year End Operational UpdateNovember 9, 2023 | finance.yahoo.comArch Therapeutics Provides Year End Operational UpdateNovember 2, 2023 | finance.yahoo.comArch Therapeutics to Present AC5® Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)April 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.September 13, 2023 | finance.yahoo.comArch Therapeutics Provides AC5® Commercialization UpdateSeptember 8, 2023 | finanznachrichten.deArch Therapeutics, Inc.: Arch Therapeutics Completes Financing as Bridge to UplistingSeptember 7, 2023 | finance.yahoo.comArch Therapeutics Completes Financing as Bridge to UplistingJuly 8, 2023 | health.usnews.comDr. Arth PatelJune 13, 2023 | travel.usnews.comDouble ArchApril 25, 2023 | finance.yahoo.comArch Therapeutics to Present AC5® Advanced Wound System at 2023 Symposium on Advanced Wound Care (“SAWC”)April 5, 2023 | finance.yahoo.comDedicated HCPCS Billing Code for Arch Therapeutics’ AC5® Advanced Wound System Now In EffectMarch 20, 2023 | investing.comArch Therapeutics Inc (ARTHD)March 9, 2023 | finance.yahoo.comArch Therapeutics’ AC5® Advanced Wound System Receives Dedicated HCPCS Billing Code from The Centers for Medicare & Medicaid ServicesMarch 7, 2023 | finance.yahoo.comArch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of AC5® Advanced Wound System in Government FacilitiesFebruary 23, 2023 | benzinga.comArch Therapeutics Inc Stock (OTC:ARTHD), Earnings Estimates, EPS, and RevenueJanuary 24, 2023 | msn.comWound products developer Arch Therapeutics files for uplisting, $35M offering (update)January 18, 2023 | finanznachrichten.deArch Therapeutics, Inc.: Arch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National ExchangeJanuary 18, 2023 | finance.yahoo.comArch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound SystemJanuary 17, 2023 | finance.yahoo.comArch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National ExchangeDecember 5, 2022 | finance.yahoo.comThe Centers for Medicare & Medicaid Services Makes Preliminary Recommendation to Establish New HCPCS Billing Code Dedicated to Arch Therapeutics’ AC5® Advanced Wound SystemOctober 20, 2022 | seekingalpha.comARTH Arch Therapeutics, Inc.October 18, 2022 | yahoo.comKey Opinion Leaders Presented Arch Therapeutics’ AC5® Advanced Wound System at 2022 Symposium on Advanced Wound Care (SAWC) FallSee More Headlines Receive ARTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/20/2024Today4/25/2024Next Earnings (Estimated)5/20/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolOTCMKTS:ARTH Previous SymbolNASDAQ:ARTH CUSIPN/A CIK1537561 Webwww.archtherapeutics.com Phone(617) 431-2313FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,980,000.00 Net Margins-6,809.45% Pretax Margin-6,808.58% Return on EquityN/A Return on Assets-386.74% Debt Debt-to-Equity RatioN/A Current Ratio0.16 Quick Ratio0.04 Sales & Book Value Annual Sales$80,000.00 Price / Sales69.92 Cash FlowN/A Price / Cash FlowN/A Book Value($2.43) per share Price / Book-0.49Miscellaneous Outstanding Shares4,740,000Free Float4,529,000Market Cap$5.59 million OptionableNot Optionable Beta3.52 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Terrence W. Norchi M.D. (Age 59)Co-Founder, Chairman, President & CEO Comp: $450.5kMr. Michael S. Abrams (Age 54)CFO & Treasurer Comp: $325kDr. Rutledge Ellis-Behnke Ph.D.Co-Founder & Scientific AdvisorMr. Shawn CarlsonVice President of SalesKey CompetitorsEncisionOTCMKTS:ECIAVenus ConceptNASDAQ:VEROAcutus MedicalNASDAQ:AFIBAvingerNASDAQ:AVGRTitan MedicalNASDAQ:TMDIFView All Competitors ARTH Stock Analysis - Frequently Asked Questions How have ARTH shares performed in 2024? Arch Therapeutics' stock was trading at $7.24 at the start of the year. Since then, ARTH stock has decreased by 83.7% and is now trading at $1.18. View the best growth stocks for 2024 here. Are investors shorting Arch Therapeutics? Arch Therapeutics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 13,100 shares, an increase of 5.6% from the March 31st total of 12,400 shares. Based on an average trading volume of 6,600 shares, the short-interest ratio is presently 2.0 days. View Arch Therapeutics' Short Interest. When is Arch Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ARTH earnings forecast. How were Arch Therapeutics' earnings last quarter? Arch Therapeutics, Inc. (OTCMKTS:ARTH) announced its quarterly earnings data on Tuesday, February, 20th. The biotechnology company reported ($0.57) earnings per share for the quarter. The biotechnology company earned $0.05 million during the quarter. What other stocks do shareholders of Arch Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arch Therapeutics investors own include Anavex Life Sciences (AVXL), POET Technologies (POETF), Aptose Biosciences (APTO), Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), SCYNEXIS (SCYX), Bellerophon Therapeutics (BLPH), Sorrento Therapeutics (SRNE), Biocept (BIOC) and Aurinia Pharmaceuticals (AUPH). How do I buy shares of Arch Therapeutics? Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ARTH) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsThe World's First "$20 Trillion Drug?"Behind the MarketsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry ResearchForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arch Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
